PocketEdge
← All news

Desk note · industry · Pharmaceuticals / global health

Dr Reddy’s won tentative US approval to sell a $40-a-year HIV prevention shot

Dr. Reddy’s Laboratories said on 2 November 2026 that the US Food and Drug Administration granted tentative approval for its generic lenacapavir injection for HIV prevention, the first among six Gilead licensees, with global health agencies citing an expected price near $40 per year for low- and middle-income markets versus about $28,000 for branded Yeztugo in the United States.

2 Nov 2026 · 2 min read

Key takeaways

  • •The US FDA issued tentative approval for Dr Reddy’s generic lenacapavir, a twice-yearly injectable HIV prevention medicine, making the Indian company the first licensed generic manufacturer to clear the agency’s quality and efficacy bar.
  • •Tentative approval lets global procurement bodies rely on FDA assessments even though US patent exclusivity still blocks American sales; rollout across roughly 120 licensed low- and middle-income countries is expected from 2027 with initial doses reaching select nations by late 2026.
  • •Global health groups said the generic could price near $40 per patient per year compared with about $28,000 annually for branded Yeztugo in the US, with Unitaid and others supporting regulatory and supply work.

What's going on here?

On 2 November 2026, Dr. Reddy’s Laboratories announced that the US Food and Drug Administration granted tentative approval for its generic version of lenacapavir injection used for HIV pre-exposure prophylaxis. The Hyderabad-based company was the first of six manufacturers licensed by Gilead Sciences to reach that milestone. FDA tentative approval confirms the product meets safety, efficacy, and manufacturing standards but does not allow commercial launch in the United States while patent or exclusivity blocks remain. The decision still matters for public-health buyers: agencies can lean on the FDA file when approving imports for low- and middle-income countries covered under voluntary licences. Global health officials quoted in wire reports said initial supplies could reach a few low-income countries by the end of 2026, with broader rollout across eligible nations from 2027, and cited an expected generic price near $40 per patient per year against roughly $28,000 for branded Yeztugo in the US.

What does this mean?

Lenacapavir offered nearly complete protection in large trials, and a twice-yearly shot removes daily pill fatigue that derails prevention programmes. Price and regulatory speed determine whether ministries of health can add it to national formularies alongside condoms and oral PrEP. Tentative FDA clearance accelerates paperwork in countries that use reliance pathways, which is why Unitaid highlighted faster procurement. For Dr Reddy’s, the win is reputational and volume-driven in export markets rather than immediate US revenue. Indian manufacturers already supply a large share of global antiretrovirals; adding lenacapavir extends that role into long-acting prevention.

Why should I care?

If you follow Indian pharma exports, treat this as a policy and access story, not a one-day stock move. Public-health NGOs will track which African and Asian countries receive first shipments and whether $40 pricing holds in tenders. Competitors such as Hetero, also working on lenacapavir with philanthropic partners, may follow with their own regulatory filings. Watch WHO prequalification steps, Gilead licence geography, and Indian government statements on domestic HIV prevention budgets even though the initial launch focus is overseas.

More desk notes

Disclaimer

For informational purposes only. Not investment advice. Verify with filings and a licensed adviser.